It is suggested that Remdesivir should be considered a preferred option in the treatment of severe cases of COVID-19 in Brazil, supporting the formulation of public health policies.
Abstract
The COVID-19 pandemic has imposed unprecedented challenges on health systems globally, with high hospitalization and mortality rates, justifying the emergency adoption of pharmacological interventions in several countries, including Brazil. The objective of this article is to describe the treatments administered and assess the risk of mortality among hospitalized patients with COVID-19 in Brazil. A retrospective cohort study was based on secondary data from Sivep-Gripe available from January 2022 through August 2024. Poisson regression was used to estimate the relative risk of mortality, considering demographic and clinical variables, and treatments administered. A total of 1,721 cases were analyzed. Patients treated with Nirmatrelvir-Ritonavir, Molnupiravir, or Baricitinib had a 2.52 (95%CI: 1.76-3.62), 4.02 (95%CI: 2.77-5.82), and 3.96 (95%CI: 2.93-5.36) times greater risk of mortality, respectively, compared to those treated with Remdesivir. The analysis indicated that Remdesivir was more effective for severe patients, possibly reducing mortality. The results suggest that Remdesivir should be considered a preferred option in the treatment of severe cases of COVID-19 in Brazil, supporting the formulation of public health policies.
Coronavirus disease 2019 (COVID-19) pandemic and its rising death toll have become a global issue. To address the disease's evolving nature, it is crucial to identify factors influencing its severity. The purpose of this study was to look at the risk factors for death in COVID-19 patients with pulmonary involvement. A...
Touba Narimani Moghadam, Vahid Rajab Nezhadi, S. Ardeshiri et al.· Journal of Current Biomedica...· 0 citations
Background:
The development of vaccines has played a significant role in managing the pandemic of COVID-19. The objective of this study was to investigate the impact of COVID-19 vaccination on mortality and intensive care unit (ICU) admissions.
Methods:
This retrospective, single-center cohort study included hospitaliz...
Julian Madrid· Chulalongkorn Medical Journa...· 0 citations
Aim.
The aim of the study is to assess the incidence and risk factors of bacteremia in hospitalized patients with COVID-19 during different periods of the pandemic.
Methods.
The study included 11203 patients diagnosed with COVID-19 who were hospitalize in Minsk City Clinical Infectious diseases Hospital, from...
K. A. Silvanovich, D. Litvinchuk· Medical Journal· 0 citations
COVID-19 has placed a heavy burden on healthcare systems, especially in resource limited settings where simple and affordable tools are needed to identify patients at high risk of death. This study aimed to evaluate routine laboratory biomarkers associated with mortality among hospitalized COVID-19 patients. A retrospe...
Danis Pertiwi, Rahayu, A. Aulia et al.· Jurnal kesehatan masyarakat· 0 citations
Rationale: This study aims to analyze data from patients who developed anemia during the COVID-19 pandemic and assess the risk of developing different types of anemia among patients diagnosed with COVID-19.
Methods: This retrospective cohort study used the National Inpatient Sample (2020–2021). We included males and f...
F. Martinez-Nachon, Alan Araiza, J. Iglesias et al.· Journal of Independent Medic...· 0 citations
This Peruvian cohort documents how tocilizumab was used, in terms of timing and dose, during the first pandemic wave in a resource-constrained setting, during 2020, before randomized clinical trial evidence supporting its use became available.
Enrique Morello Bustios, Socorro Castro, C. Ticona et al.· COVID· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.